
5.99.018

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Miscellaneous Products	Original Policy Date:	July 10, 2020
Subject:	Uplizna	Page:	1 of 5

Last Review Date: March 6, 2026

Uplizna

Description

Uplizna (inebilizumab-cdon)

Background

Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody. CD19 is a cell surface antigen that presents on pre-B and mature B lymphocytes. Following binding to B lymphocytes, Uplizna results in antibody-dependent cellular cytotoxicity (1).

Regulatory Status

FDA-approved indications: Uplizna is a CD19-directed cytolytic antibody indicated for the treatment of: (1)

- Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
- Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
- Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.

Uplizna is contraindicated in patients with active hepatitis B infection or active or untreated latent tuberculosis. Prior to initiating Uplizna, patients should be screened for Hepatitis B virus (HBV) and patient should be evaluated for active tuberculosis and tested for latent infection (1).

Immunizations should be administered at least 4 weeks prior to initiation of Uplizna. The safety of immunization with live or live-attenuated vaccines following Uplizna therapy has not been

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Miscellaneous Products	Original Policy Date:	July 10, 2020
Subject:	Uplizna	Page:	2 of 5

studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion (1).

Uplizna can cause fetal harm. Females of reproductive potential should be advised to use effective contraception while receiving Uplizna and for at least 6 months after the last dose (1).

The safety and effectiveness of Uplizna in pediatric patients less than 18 years of age have not been established (1).

Related policies

Enspryng, Soliris

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Uplizna may be considered **medically necessary** if the conditions indicated below are met.

Uplizna may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Neuromyelitis optica spectrum disorder (NMOSD)
 - a. Anti-aquaporin-4 (AQP4) antibody positive
2. Immunoglobulin G4-related disease (IgG4-RD)
3. Generalized myasthenia gravis (gMG)
 - a. Presence of autoantibodies against AChR or MuSK
 - b. Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV
 - c. Documented baseline score of **ONE** of the following:
 - i. MG-Activities of Daily Living (MG-ADL) total score \geq 11 **OR** total score between 6 and 10 with at least 50% of this score attributed to non-ocular items

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Miscellaneous Products	Original Policy Date:	July 10, 2020
Subject:	Uplizna	Page:	3 of 5

(http://c.peerview.com/inReview/programs/150204324/downloads/PVI_practiceaids_RM U.pdf)

- ii. Quantitative Myasthenia Gravis (QMG) total score ≥ 11
(<https://myasthenia.org/wp-content/uploads/Portals/0/QMG.pdf>)
- d. Patient has had an inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
 - i. acetylcholinesterase inhibitor
 - ii. azathioprine
 - iii. cyclosporine
 - iv. mycophenolate mofetil
 - v. tacrolimus
 - vi. methotrexate
 - vii. cyclophosphamide

AND ALL of the following:

- a. **NO** active hepatitis B infection
- b. **NOT** given concurrently with live vaccines
- c. **NO** active or untreated latent tuberculosis
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Uplizna and for 6 months after the last dose

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Neuromyelitis optica spectrum disorder (NMOSD)
 - a. Patient has had clinical benefit from therapy (e.g., fewer relapses or improvement in flares while on Uplizna therapy)
2. Immunoglobulin G4-related disease (IgG4-RD)
 - a. Patient has had clinical benefit from therapy (e.g., fewer relapses or improvement in flares while on Uplizna therapy)
3. Generalized myasthenia gravis (gMG)
 - a. Decrease of MG-ADL or QMG total score from baseline of ≥ 2 points
(http://c.peerview.com/inReview/programs/150204324/downloads/PVI_practiceaids_RMU.pdf)
(<https://myasthenia.org/wp-content/uploads/Portals/0/QMG.pdf>)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Miscellaneous Products	Original Policy Date:	July 10, 2020
Subject:	Uplizna	Page:	4 of 5

AND ALL of the following:

- NO** active hepatitis B infection
- NOT** given concurrently with live vaccines
- NO** active or untreated latent tuberculosis
- Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Uplizna and for 6 months after the last dose

Policy Guidelines

Pre – PA Allowance

None

Prior - Approval Limits

Quantity 9 vials

Duration 12 months

Prior – Approval *Renewal* Limits

Quantity 6 vials

Duration 12 months

Rationale

Summary

Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody. CD19 is a cell surface antigen that presents on pre-B and mature B lymphocytes. Following binding to B lymphocytes, Uplizna results in antibody-dependent cellular cytotoxicity. The safety and effectiveness of Uplizna in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Uplizna while maintaining optimal therapeutic outcomes.

References

1. Uplizna [package insert]. Dublin, Ireland: Amgen Inc.; December 2025.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Miscellaneous Products	Original Policy Date:	July 10, 2020
Subject:	Uplizna	Page:	5 of 5

Policy History

Date	Action
July 2020	Addition to PA
September 2020	Annual review
December 2020	Annual review
December 2021	Annual review and reference update
December 2022	Annual review. Changed policy number to 5.99.018
December 2023	Annual review
December 2024	Annual review
April 2025	Per PI update, added indication of Immunoglobulin G4-related disease (IgG4-RD)
June 2025	Annual review
January 2026	Per PI update, added indication of gMG
March 2026	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.